An observational study in Critical Illness, sponsored by Sohag University. Completed at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-20.
Sponsored by Sohag University · Observational
Critical illness represents a complex pathophysiological state characterized by systemic inflammation, oxidative stress, immune dysregulation, and progressive multiorgan dysfunction. In the Intensive Care Unit (ICU) setting, accurate and timely risk stratification remains paramount for optimizing patient outcomes, guiding therapeutic decision-making, and ensuring appropriate allocation of limited healthcare resources .Red cell distribution width (RDW), a quantitative measure of anisocytosis, has emerged as a powerful independent predictor of adverse outcomes across diverse clinical contexts, including sepsis, cardiovascular disease, and general ICU populations . Elevated RDW reflects dysregulated erythropoiesis and is mechanistically linked to chronic inflammation, oxidative stress, nutritional deficiencies, and impaired hematopoietic progenitor cell function .Mean corpuscular hemoglobin concentration (MCHC) represents the average hemoglobin concentration within erythrocytes and provides valuable information regarding red blood cell integrity, hemoglobin synthesis, and oxygen-carrying capacity. Reduced MCHC values are observed in conditions associated with impaired hemoglobin production, while elevated values may indicate hemolysis or red cell dehydration .Emerging evidence suggests that composite hematological ratios may enhance predictive performance compared to individual parameters by integrating complementary physiological information. The RDW:MCHC ratio is a novel biomarker that combines variability in red cell size with hemoglobin concentration, potentially offering a more comprehensive reflection of the underlying pathophysiological derangements characteristic of critical illness
1,780 studies on the registry are indexed under Critical Illness; 442 are open to participants now.
This study's enrollment of 200 is above the median of 140 across 814 observational studies indexed under Critical Illness.
Browse Critical Illness studies →Sohag University is the lead sponsor of 1,232 studies on the registry; 638 are open to participants now.
Counted across the registry records on this site, refreshed daily.
All consecutive adult patients (≥18 years) admitted to the Intensive Care Unit (ICU) at Sohag University Hospital, a tertiary care referral hospital, who meet the eligibility criteria. The study population includes both obstetric (pregnant and postpartum) and non-obstetric (non-pregnant) critically ill patients. Patients with documented hematological malignancies or recent blood transfusion (within 7 days prior to ICU admission) are excluded.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
ICU stay of at least 24 hours duration
Available complete blood count (CBC) parameters at the time
Exclusion Criteria:
Documented hematological (including leukemia, lymphoma, and myelodysplastic syndromes)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1. ICU Mortality
All-cause mortality during ICU stay, assessed through prospective follow-up from admission until discharge or death
Time frame: From ICU admission to ICU discharge or death, up to 90 days
ICU Length of Stay
Duration of intensive care unit admission measured in days from ICU admission until ICU discharge.
Time frame: From ICU admission to ICU discharge (assessed up to 90 days)
Plan to share: No
No publications or documents are linked to this record.
Ran from Jul 2026 to primary completion in Aug 2026, 0 months.
Of 439 non-industry observational studies under Critical Illness, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 45. This study's 0 months is below that.
Counting every sponsor, half of 442 studies reached it within 23 months; a quarter within 12 and three quarters within 46.
Critical Illness covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.